Another possibility is that anti-cancer drugs activate TrpA1 via the conserved ankyrin repeat domain (ARD), which consists of a large number of tandem ankyrin repeats located in the N-terminus of all TrpA1 channels and required for normal TrpA1 function including responses to noxious chemicals [78] [31,40,79]. Here, TRPA1 is linked to cancer.